Zebra...The Good...1) Efficacy reported as satisfactory more advanced ED cases, 2) IMS script data leveling with upturn expected in next 1-3 weeks, 3) $4.00 book value, 4) $38M cash ending this quarter, 5) Current SGA expenses averaging approx $18M per quarter. Possible downsize of direct sales force with outside agreements with larger pharmaceutical companies operating on commission basis. Would bring SGA expenses into $5M per quarter range, 6) Pending new plant approval which will increase product margins. Current costs approx $5.75 per unit. New plant product estimated at $2.75 per unit with production totally in house, 7) International sales estimated this quarter at $10M, $12M 3'rd, $14M 4'th, 8) 14M shares shorted, 9) Local side effects with proven safety. Non systemic option, 10) contrarian mentality, against the herd.....The Bad...1) Pending class action suits, 2) The Pill(s), 3) Declining scripts, 4) Delayed plant approval, 5) Quarter to quarter cash reduction, 6)Management percieved as shareholder unfriendly,7)Reduced earnings estimates and downgrades,8)Out of favor with the street,9)Conflicting efficacy reports,10)Annoying side effects and application difficulties.......The Ugly...Just look at the chart....PS...When the scripts turn so will the sheep
|
